LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Holders of 5% or more of LENZ
Holders whose latest Schedule 13D or 13G filing reports 5% or more of LENZ Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 15.10%4.26M shares | – | May 9, 20251 filing | May 9, 2025 | SEC |
| Paradigm Biocapital Advisors LP | 13G | 5.20%1.42M shares | New | Mar 27, 20251 filing | Mar 27, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
7 Schedule 13D and 13G filings on LENZ Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 20254:20 PM ET | Versant Venture Capital VI, L.P.and 8 others | 13D/A | 4.10%1.18M shares | −0.80 ppfrom 4.90%Below 5% | Sep 18, 2025 | SEC |
| Aug 20, 20255:13 PM ET | Versant Venture Capital VI, L.P.and 8 others | 13D/A | 4.90%1.40M shares | −0.70 ppfrom 5.60%Below 5% | Aug 18, 2025 | SEC |
| Jul 14, 20254:50 PM ET | Versant Venture Capital VI, L.P.and 8 others | 13D/A | 5.60%1.58M shares | −1.40 ppfrom 7.00% | Jul 10, 2025 | SEC |
| Jun 24, 20254:21 PM ET | Versant Venture Capital VI, L.P.and 8 others | 13D/A | 7.00%1.97M shares | −0.50 ppfrom 7.50% | Jun 20, 2025 | SEC |
| Jun 12, 20254:49 PM ET | Versant Venture Capital VI, L.P.and 8 others | 13D/A | 7.50%2.10M shares | – | Jun 10, 2025 | SEC |
| May 9, 20254:19 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 15.10%4.26M shares | – | May 7, 2025 | SEC |
| Mar 27, 20254:21 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 5.20%1.42M shares | New | Mar 20, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell LENZ Therapeutics, Inc. shares.
No Form 144 notices for LENZ Therapeutics, Inc. are on file.